AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +72

Andra AP fonden Acquires 86,969 Shares of AbbVie Inc. $ABBV

📈 Andra AP fonden increased its AbbVie holdings by 44.2% in Q1, adding 86,969 shares for a total value of $61.7 million.

📊 Several institutional investors including Bank of Jackson Hole Trust and Hardin Capital Partners LLC added to their stakes in the fourth quarter.

🎯 Piper Sandler reaffirmed an overweight rating with a price target of $298.00 on AbbVie shares.

📈 Cantor Fitzgerald raised its price objective from $240.00 to $265.00 and maintained an overweight rating.

💰 JPMorgan Chase boosted its target price from $260.00 to $280.00 with an overweight rating.

📉 Citigroup increased its target price to $260.00 but issued a neutral rating on the stock.

🏦 UBS Group raised its price target to $260.00 and assigned a neutral rating to AbbVie.

📈 AbbVie reported quarterly revenue of $15 billion, exceeding analyst expectations of $14.72 billion.

💵 The company posted earnings per share of $2.65, beating the consensus estimate of $2.59.

🚀 Revenue grew 12.4% year-over-year compared to the same quarter in the previous year.

💸 AbbVie announced a quarterly dividend of $1.73 per share payable on August 14th.

📉 The company reported a negative return on equity of -576.45% for the quarter.

📊 The stock currently trades at a PE ratio of 124.81 with a market cap of $447.66 billion.

📈 AbbVie's revenue beat expectations by $0.28 billion in the most recent quarterly report.

🏥 The company focuses on therapies for complex medical conditions including immunology and oncology.

Bullish Signals
  • Andra AP fonden significantly increased its stake in AbbVie by 44.2% in Q1, adding $61.7 million to its portfolio.
  • Multiple major analysts raised price targets, with Piper Sandler setting a target of $298 and JPMorgan Chase at $280.
  • AbbVie reported quarterly revenue of $15 billion, beating analyst expectations of $14.72 billion.
  • The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59.
  • Revenue grew 12.4% year-over-year, demonstrating strong business performance.
  • AbbVie announced a quarterly dividend of $1.73 per share payable on August 14th.
Risk Factors
  • The company reported a negative return on equity of -576.45% for the quarter.
  • Citigroup and UBS Group issued neutral ratings despite raising price targets.
  • AbbVie's stock trades at a high PE ratio of 124.81, indicating potential valuation concerns.
Full Analysis
Andra AP fonden significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, acquiring an additional 86,969 shares to bring its total holding to 283,811 shares valued at $61.7 million. This investment makes AbbVie the fund's 18th largest position, representing approximately 0.8% of its total portfolio. Several other institutional investors, including Bank of Jackson Hole Trust and Hardin Capital Partners LLC, also added to their positions in the fourth quarter. Analyst sentiment remains broadly positive with major firms raising price targets for AbbVie stock. Piper Sandler reaffirmed an overweight rating with a $298 target, while Cantor Fitzgerald, JPMorgan Chase, Citigroup, and UBS Group all increased their price objectives between $240 and $280. The consensus average target price stands at $267.67 based on ratings from MarketBeat. AbbVie recently reported strong quarterly financial results with revenue of $15 billion, beating analyst expectations of $14.72 billion by 1.9%. The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59, and achieved a year-over-year revenue growth of 12.4%. Additionally, the company announced a quarterly dividend of $1.73 per share payable on August 14th to stockholders of record as of July 15th.